PURPOSE: We undertook a systematic approach to identify breast cancer (BC) marker genes with molecular assays and evaluated these marker genes for the detection of minimal residual disease in peripheral blood mononuclear cells (PBMCs). EXPERIMENTAL DESIGN: We used serial analysis of gene expression to identify a range of genes that were expressed in BC but absent in the expression profiles of blood and bone marrow cells. Next, we evaluated a panel of four marker genes (p1B, PS2, CK19, and EGP2) by real-time quantitative PCR in 103 PBMC samples from patients with metastatic BC (stage III/IV) and in 96 PBMC samples from healthy females. RESULTS: Increased marker gene expression of at least one marker was seen in 33 of 103 patients. Using quadratic discriminant analysis including all four marker genes, we determined a discriminant value with 29% positivity in the BC patient group that did not yield false positive results among the healthy females. CONCLUSIONS: Real-time PCR for the simultaneous expression of multiple cancer-specific genes may ensure the specificity required for the clinical application of mRNA expression-based assays for occult tumor cells.
PURPOSE: We undertook a systematic approach to identify breast cancer (BC) marker genes with molecular assays and evaluated these marker genes for the detection of minimal residual disease in peripheral blood mononuclear cells (PBMCs). EXPERIMENTAL DESIGN: We used serial analysis of gene expression to identify a range of genes that were expressed in BC but absent in the expression profiles of blood and bone marrow cells. Next, we evaluated a panel of four marker genes (p1B, PS2, CK19, and EGP2) by real-time quantitative PCR in 103 PBMC samples from patients with metastatic BC (stage III/IV) and in 96 PBMC samples from healthy females. RESULTS: Increased marker gene expression of at least one marker was seen in 33 of 103 patients. Using quadratic discriminant analysis including all four marker genes, we determined a discriminant value with 29% positivity in the BC patient group that did not yield false positive results among the healthy females. CONCLUSIONS: Real-time PCR for the simultaneous expression of multiple cancer-specific genes may ensure the specificity required for the clinical application of mRNA expression-based assays for occult tumor cells.
Authors: Nagarajan Kannan; Jian Kang; Xiangjun Kong; Jianzhong Tang; Jo K Perry; Kumarasamypet M Mohankumar; Lance D Miller; Edison T Liu; Hichem C Mertani; Tao Zhu; Prudence M Grandison; Dong-Xu Liu; Peter E Lobie Journal: Neoplasia Date: 2010-12 Impact factor: 5.715
Authors: Monica M Reinholz; Kathleen A Kitzmann; Kathleen Tenner; David Hillman; Amylou C Dueck; Timothy J Hobday; Donald W Northfelt; Alvaro Moreno-Aspitia; Vivek Roy; Betsy LaPlant; Jake B Allred; Philip J Stella; Wilma L Lingle; Edith A Perez Journal: Clin Cancer Res Date: 2011-10-05 Impact factor: 12.531
Authors: María José Serrano Fernádez; Juan Carlos Alvarez Merino; Iñigo Martínez Zubiaurre; Ana Fernández García; Pedro Sánchez Rovira; José Antonio Lorente Acosta Journal: Clin Transl Oncol Date: 2009-10 Impact factor: 3.405